Wave Life Sciences Ltd (WVE)

$8.56

-0.17

(-1.95%)▲

Market is closed - opens 7 PM, 16 Oct 2024

Performance

  • $8.51
    $8.76
    $8.56
    downward going graph

    0.58%

    Downside

    Day's Volatility :2.85%

    Upside

    2.28%

    downward going graph
  • $3.50
    $9.92
    $8.56
    downward going graph

    59.11%

    Downside

    52 Weeks Volatility :64.72%

    Upside

    13.71%

    downward going graph

Returns

PeriodWave Life Sciences LtdSector (Health Care)Index (Russel 2000)
3 Months
45.74%
4.7%
0.0%
6 Months
52.09%
11.6%
0.0%
1 Year
56.17%
18.9%
0.0%
3 Years
69.51%
20.9%
-21.9%

Highlights

Market Capitalization
1.3B
Book Value
-$0.03
Earnings Per Share (EPS)
-0.57
PEG Ratio
0.0
Wall Street Target Price
16.0
Profit Margin
-66.5%
Operating Margin TTM
-177.72%
Return On Assets TTM
-23.84%
Return On Equity TTM
-1920.16%
Revenue TTM
110.5M
Revenue Per Share TTM
0.93
Quarterly Revenue Growth YOY
-10.9%
Gross Profit TTM
-73.6M
EBITDA
-79.4M
Diluted Eps TTM
-0.57
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.04
EPS Estimate Next Year
-1.0
EPS Estimate Current Quarter
-0.21
EPS Estimate Next Quarter
-0.25

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Wave Life Sciences Ltd(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 86.92%

Current $8.56
Target $16.00

Company Financials

FY18Y/Y Change
Revenue
14.4M
↑ 289.15%
Net Income
-146.7M
↑ 43.73%
Net Profit Margin
-1.0K%
↑ 1737.29%
FY19Y/Y Change
Revenue
16.0M
↑ 10.89%
Net Income
-179.5M
↑ 22.4%
Net Profit Margin
-1.1K%
↓ 105.61%
FY20Y/Y Change
Revenue
20.1M
↑ 25.61%
Net Income
-149.9M
↓ 16.48%
Net Profit Margin
-746.68%
↑ 376.36%
FY21Y/Y Change
Revenue
41.0M
↑ 104.03%
Net Income
-122.2M
↓ 18.45%
Net Profit Margin
-298.42%
↑ 448.26%
FY22Y/Y Change
Revenue
3.6M
↓ 91.09%
Net Income
-161.8M
↑ 32.38%
Net Profit Margin
-4.4K%
↓ 4136.3%
FY23Y/Y Change
Revenue
113.3M
↑ 3005.1%
Net Income
-57.5M
↓ 64.46%
Net Profit Margin
-50.76%
↑ 4383.96%
Q1 FY23Q/Q Change
Revenue
12.9M
↑ 943.5%
Net Income
-24.5M
↓ 43.89%
Net Profit Margin
-189.69%
↑ 3338.07%
Q2 FY23Q/Q Change
Revenue
22.1M
↑ 70.98%
Net Income
-21.1M
↓ 13.95%
Net Profit Margin
-95.47%
↑ 94.22%
Q3 FY23Q/Q Change
Revenue
49.2M
↑ 122.63%
Net Income
7.3M
↓ 134.36%
Net Profit Margin
14.74%
↑ 110.21%
Q4 FY23Q/Q Change
Revenue
29.1M
↓ 40.96%
Net Income
-16.3M
↓ 324.16%
Net Profit Margin
-55.95%
↓ 70.69%
Q1 FY24Q/Q Change
Revenue
12.5M
↓ 56.85%
Net Income
-31.6M
↑ 94.13%
Net Profit Margin
-251.7%
↓ 195.75%
Q2 FY24Q/Q Change
Revenue
19.7M
↑ 57.06%
Net Income
-32.9M
↑ 4.33%
Net Profit Margin
-167.19%
↑ 84.51%
FY18Y/Y Change
Total Assets
295.9M
↑ 62.74%
Total Liabilities
222.6M
↑ 429.62%
FY19Y/Y Change
Total Assets
284.3M
↓ 3.95%
Total Liabilities
220.5M
↓ 0.93%
FY20Y/Y Change
Total Assets
279.2M
↓ 1.76%
Total Liabilities
196.5M
↓ 10.91%
FY21Y/Y Change
Total Assets
207.0M
↓ 25.87%
Total Liabilities
174.5M
↓ 11.17%
FY22Y/Y Change
Total Assets
146.4M
↓ 29.28%
Total Liabilities
191.5M
↑ 9.72%
FY23Y/Y Change
Total Assets
274.9M
↑ 87.82%
Total Liabilities
227.4M
↑ 18.78%
Q1 FY23Q/Q Change
Total Assets
267.3M
↑ 82.58%
Total Liabilities
302.0M
↑ 57.71%
Q2 FY23Q/Q Change
Total Assets
230.0M
↓ 13.95%
Total Liabilities
281.7M
↓ 6.72%
Q3 FY23Q/Q Change
Total Assets
199.9M
↓ 13.07%
Total Liabilities
240.4M
↓ 14.66%
Q4 FY23Q/Q Change
Total Assets
274.9M
↑ 37.53%
Total Liabilities
227.4M
↓ 5.39%
Q1 FY24Q/Q Change
Total Assets
235.3M
↓ 14.43%
Total Liabilities
202.0M
↓ 11.18%
Q2 FY24Q/Q Change
Total Assets
208.8M
↓ 11.24%
Total Liabilities
204.4M
↑ 1.2%
FY18Y/Y Change
Operating Cash Flow
-22.9M
↓ 72.68%
Investing Cash Flow
-9.9M
↓ 47.38%
Financing Cash Flow
65.1M
↓ 31.03%
FY19Y/Y Change
Operating Cash Flow
-188.2M
↑ 723.34%
Investing Cash Flow
-3.9M
↓ 60.58%
Financing Cash Flow
164.4M
↑ 152.56%
FY20Y/Y Change
Operating Cash Flow
-116.0M
↓ 38.38%
Investing Cash Flow
-1.3M
↓ 65.85%
Financing Cash Flow
154.5M
↓ 6.0%
FY21Y/Y Change
Operating Cash Flow
-89.0M
↓ 23.27%
Investing Cash Flow
-560.0K
↓ 58.15%
Financing Cash Flow
55.8M
↓ 63.87%
FY22Y/Y Change
Operating Cash Flow
-127.8M
↑ 43.59%
Investing Cash Flow
-1.3M
↑ 124.11%
Financing Cash Flow
67.2M
↑ 20.35%
Q1 FY23Q/Q Change
Operating Cash Flow
85.5M
↓ 355.75%
Investing Cash Flow
-489.0K
↑ 0.0%
Financing Cash Flow
35.1M
↑ 63632.73%
Q2 FY23Q/Q Change
Operating Cash Flow
-37.3M
↓ 143.56%
Investing Cash Flow
-72.0K
↓ 85.28%
Financing Cash Flow
1.8M
↓ 94.73%

Technicals Summary

Sell

Neutral

Buy

Wave Life Sciences Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Wave Life Sciences Ltd
Wave Life Sciences Ltd
45.99%
52.09%
56.17%
69.51%
-58.59%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-12.04%
12.88%
20.22%
83.33%
233.83%
Novo Nordisk A/s
Novo Nordisk A/s
-12.51%
-3.33%
18.42%
134.08%
356.57%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
4.79%
91.82%
69.4%
35.85%
250.43%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.94%
22.01%
29.63%
166.72%
175.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Wave Life Sciences Ltd
Wave Life Sciences Ltd
NA
NA
0.0
-1.04
-19.2
-0.24
NA
-0.03
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.87
26.87
1.38
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.83
40.83
1.84
3.37
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.43
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.58
0.33
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Wave Life Sciences Ltd
Wave Life Sciences Ltd
Buy
$1.3B
-58.59%
NA
-66.5%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.9B
233.83%
26.87
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$535.2B
356.57%
40.83
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$36.5B
250.43%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$125.1B
175.25%
32.84
-4.74%

Insights on Wave Life Sciences Ltd

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 12.53M → 19.69M (in $), with an average increase of 36.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, 7.25M → -32.92M (in $), with an average decrease of 140.9% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.5% return, outperforming this stock by 11.2%

Institutional Holdings

  • RA Capital Management, LLC

    11.97%

  • Maverick Capital Ltd

    5.04%

  • BlackRock Inc

    4.43%

  • M28 Capital Management LP

    4.05%

  • Adage Capital Partners Gp LLC

    3.52%

  • 683 Capital Management LLC

    3.50%

Company Information

wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.

Organization
Wave Life Sciences Ltd
Employees
266
CEO
Dr. Paul B. Bolno M.B.A., M.D.
Industry
Health Technology

Discover More

FAQs